Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy

Akinci G., AKINCI B.

RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, cilt.9, sa.2, ss.74-78, 2015 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 2
  • Basım Tarihi: 2015
  • Doi Numarası: 10.2174/1574892811666151111142554
  • Dergi Adı: RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Aerospace Database, Biotechnology Research Abstracts, Communication Abstracts, EMBASE, Metadex, Civil Engineering Abstracts
  • Sayfa Sayıları: ss.74-78
  • Anahtar Kelimeler: Diabetes, fat loss, hepatic steatosis, hypertrigly ceridemia, insulin resistance, lipodystrophy, metreleptin
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Lipodystrophies are a heterogeneous group of disorders characterized by congenital or acquired loss of adipose tissue. Recently, metreleptin, a recombinant human leptin analog, has been approved for the treatment of patients with generalized lipodystrophy. Leptin is an adipokine which has a fundamental role in glucose and lipid homeostasis. Metreleptin treatment has been demonstrated to improve metabolic abnormalities such as hyperglycemia, hypertriglyceridemia, increased hepatic fat content and elevated liver enzymes alanine transaminase and aspartate transaminase in patients with generalized lipodystrophy, and to correct hyperphagia that likely occurs as a result of leptin deficiency. Limited data has also suggested that metreleptin treatment might be beneficial on metabolic abnormalities in patients with partial lipodystrophy. This review focuses on potential benefits of metreleptin in various forms of non-HIV associated lipodystrophy. Safety issues have been discussed. Recent patent submissions have also been reviewed.